Maravai LifeSciences Holdings Inc
(FRA:MAR)
€
5.1
-0.20 (-3.77%)
Market Cap: 764.86 Mil
Enterprise Value: 994.69 Mil
PE Ratio: 0
PB Ratio: 4.12
GF Score: 63/100 Maravai LifeSciences Holdings Inc at Credit Suisse Healthcare Conference Transcript
Nov 08, 2022 / 08:50PM GMT
Release Date Price:
€14.07
(+0.27%)
Daniel Louis Leonard;dit Suisse AG
CrÃ;Research Division - Research Analyst
© -
Our next presentation, we have Maravai. We're lucky to have with us today, Kevin Herde, Chief Financial Officer; and Brian Neel, Chief Operating Officer. I'm Dan Leonard, I cover the life sciences industry for Credit Suisse. Kevin and Brian, thank you for coming.
Kevin M. Herde
Maravai LifeSciences Holdings, Inc. - Executive VP & CFO
Thanks, Dan.
Questions & Answers
Daniel Louis Leonard;dit Suisse AG
CrÃ;Research Division - Research Analyst
© -
I was hoping to start off the fireside with a brief overview of Maravai for folks who might not be familiar?
Kevin M. Herde
Maravai LifeSciences Holdings, Inc. - Executive VP & CFO
Yes, certainly happy to do that. So Maravai LifeSciences, obviously, a life sciences company, really focused in on 2 segments, our Nucleic Acid production segment and our Biologics Safety Testing segment.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot